Multiple-dose study to examine safety, tolerability, pharmacokinetics, and pharmacodynamics of LY2148568 long-acting release in Japanese patients with type 2 diabetes mellitus.

Trial Profile

Multiple-dose study to examine safety, tolerability, pharmacokinetics, and pharmacodynamics of LY2148568 long-acting release in Japanese patients with type 2 diabetes mellitus.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2018

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Apr 2018 Results of pooled post hoc analysis of this and other ten trials assessing the relationship of heart rate changes with baseline heart rate and identifying patient characteristics associated with changes in heart rate in the Exenatide QW development program published in the Diabetes Therapy
    • 10 Jun 2017 Biomarkers information updated
    • 16 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top